Argenica Therapeutics Ltd has released a press release.
Successful Completion of Final Pre-Clinical PK Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
Story so far
Earlier from Argenica Therapeutics
- GLP Safety Studies Successfully Completed
- Maximum Tolerated Dose Successfully Established in Studies
- Argenica Appoints CEO Dr Liz Dallimore Managing Director
- Positive Preclincal Data on Efficacy in New Indication
- Peer Reviewed Paper Published on Preclinical Study
Later from Argenica Therapeutics
- Argenica Therapeutics: Proposed issue of securities - AGN
- Argenica Successfully Completes $5.5m Placement
- Application for quotation of securities - AGN
- Peer Reviewed Paper Published on Preclinical Safety Study
- Appendix 4E & Annual Report 30 June 2022
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics